TY - JOUR
T1 - A serum microRNA classifier for the diagnosis of sarcomas of various histological subtypes
AU - Asano, Naofumi
AU - Matsuzaki, Juntaro
AU - Ichikawa, Makiko
AU - Kawauchi, Junpei
AU - Takizawa, Satoko
AU - Aoki, Yoshiaki
AU - Sakamoto, Hiromi
AU - Yoshida, Akihiko
AU - Kobayashi, Eisuke
AU - Tanzawa, Yoshikazu
AU - Nakayama, Robert
AU - Morioka, Hideo
AU - Matsumoto, Morio
AU - Nakamura, Masaya
AU - Kondo, Tadashi
AU - Kato, Ken
AU - Tsuchiya, Naoto
AU - Kawai, Akira
AU - Ochiya, Takahiro
N1 - Funding Information:
The study was supported by grants from the Japan Agency for Medical Research and Development, and the Development and New Energy and Industrial Technology Development Organization, Japan. The National Cancer Center Biobank was supported by the National Cancer Center Research and Development Fund, Japan. We thank Tomomi Fukuda, Takumi Sonoda, Hiroko Tadokoro, and Kamakura Techno-Science for performing the microarray assays; Noriko Abe, Michiko Ohori, Kousuke Hirota, Cuneyd Parlayan, Yuuki Tani, and Takumi Sonoda for picking up samples from the freezing room; Kazuki Sudo for independent confirmation of participant eligibility; and Yusuke Yamamoto for critically reading the manuscript.
Publisher Copyright:
© 2019, The Author(s).
PY - 2019/12/1
Y1 - 2019/12/1
N2 - Due to their rarity and diversity, sarcomas are difficult to diagnose. Consequently, there is an urgent demand for a novel diagnostic test for these cancers. In this study, we investigated serum miRNA profiles from 1002 patients with bone and soft tissue tumors representing more than 43 histological subtypes, including sarcomas, intermediate tumors, and benign tumors, to determine whether serum miRNA profiles could be used to specifically detect sarcomas. Circulating serum miRNA profiles in sarcoma patients were clearly distinct from those in patients with other types of tumors. Using the serum levels of seven miRNAs, we developed a molecular detector, Index VI, that could distinguish sarcoma patients from benign and healthy controls with remarkably high sensitivity (90%) and specificity (95%), regardless of histological subtype. Index VI provides an approach to the early and precise detection of sarcomas, potentially leading to curative treatment and longer survival.
AB - Due to their rarity and diversity, sarcomas are difficult to diagnose. Consequently, there is an urgent demand for a novel diagnostic test for these cancers. In this study, we investigated serum miRNA profiles from 1002 patients with bone and soft tissue tumors representing more than 43 histological subtypes, including sarcomas, intermediate tumors, and benign tumors, to determine whether serum miRNA profiles could be used to specifically detect sarcomas. Circulating serum miRNA profiles in sarcoma patients were clearly distinct from those in patients with other types of tumors. Using the serum levels of seven miRNAs, we developed a molecular detector, Index VI, that could distinguish sarcoma patients from benign and healthy controls with remarkably high sensitivity (90%) and specificity (95%), regardless of histological subtype. Index VI provides an approach to the early and precise detection of sarcomas, potentially leading to curative treatment and longer survival.
UR - http://www.scopus.com/inward/record.url?scp=85063354636&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85063354636&partnerID=8YFLogxK
U2 - 10.1038/s41467-019-09143-8
DO - 10.1038/s41467-019-09143-8
M3 - Article
C2 - 30898996
AN - SCOPUS:85063354636
SN - 2041-1723
VL - 10
JO - Nature communications
JF - Nature communications
IS - 1
M1 - 1299
ER -
